Faes Farma SA (ES:FAE)
BME:FAE
Top Page
Faes Farma
(BME:FAE)
Select Model
Select Model
Rating:51Neutral
Price Target:
€5.00
▼(-4.21% Downside)
Action:DowngradedDate:03/05/26
The score is driven primarily by financial performance: 2025 shows a meaningful step-down (lower revenue, margin compression, weaker cash conversion, and higher leverage) versus prior years. Technicals are also a drag with weak momentum and the price below key moving averages. Valuation and the dividend offer partial support but are not strong enough to offset the recent fundamental and momentum softness.
Positive Factors
Historical profitability
Sustained high gross and net margins from 2020–2024 indicate durable earnings power and operating leverage in the core business. This historical profitability supports ongoing R&D, manufacturing investment and provides a buffer to absorb near-term shocks while pursuing long-term product development.
Negative Factors
2025 revenue and margin deterioration
A meaningful revenue decline and sharp margin compression in 2025 signal structural pressure on sales mix, pricing or product competitiveness. If persistent, this erodes reinvestment capacity for R&D and commercialization and heightens execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Historical profitability
Sustained high gross and net margins from 2020–2024 indicate durable earnings power and operating leverage in the core business. This historical profitability supports ongoing R&D, manufacturing investment and provides a buffer to absorb near-term shocks while pursuing long-term product development.
Read all positive factors
Faes Farma (FAE) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€1.40B
Dividend Yield3.51%
Average Volume (3M)130.56K
Price to Earnings (P/E)20.2
Beta (1Y)0.45
Revenue Growth11.04%
EPS Growth8.29%
CountryES
Employees1,775
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.09
Shares Outstanding316,223,940
10 Day Avg. Volume112,243
30 Day Avg. Volume130,562
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)2.16
Price to Sales (P/S)2.63
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)€716.83M
Faes Farma Business Overview & Revenue Model
Company Description
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over...
How the Company Makes Money
Faes Farma generates revenue through multiple key streams, primarily from the sale of its pharmaceutical products, which include patented drugs, generics, and over-the-counter medications. The company operates in various international markets, all...
Faes Farma Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 610.46M | 493.65M | 451.17M | 438.75M | 398.56M |
| Gross Profit | 228.46M | 326.54M | 297.12M | 282.01M | 252.40M |
| EBITDA | 101.80M | 128.33M | 122.93M | 121.35M | 110.84M |
| Net Income | 79.63M | 111.36M | 91.90M | 89.50M | 82.39M |
Balance Sheet | |||||
| Total Assets | 1.34B | 853.08M | 776.03M | 725.67M | 641.76M |
| Cash, Cash Equivalents and Short-Term Investments | 130.09M | 72.14M | 47.75M | 84.10M | 73.41M |
| Total Debt | 409.91M | 7.79M | 23.90M | 32.69M | 16.44M |
| Total Liabilities | 594.19M | 126.46M | 112.68M | 123.39M | 103.70M |
| Stockholders Equity | 744.80M | 725.87M | 662.36M | 601.08M | 536.53M |
Cash Flow | |||||
| Free Cash Flow | 62.38M | 75.95M | -1.22M | 25.84M | 20.23M |
| Operating Cash Flow | 78.49M | 115.47M | 100.97M | 106.79M | 79.64M |
| Investing Cash Flow | -299.02M | -34.18M | -97.36M | -92.17M | -83.48M |
| Financing Cash Flow | 273.62M | -51.71M | -35.38M | -18.46M | -17.12M |
Faes Farma Technical Analysis
Negative
5.22
Price Trends
4.99
Negative
4.89
Negative
4.61
Negative
Market Momentum
-0.17
Positive
32.31
Neutral
12.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:FAE, the sentiment is Negative. The current price of 5.22 is above the 20-day moving average (MA) of 4.71, above the 50-day MA of 4.99, and above the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 32.31 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:FAE.
Faes Farma Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €3.97B | 23.13 | 23.03% | 1.50% | -9.39% | -25.92% | |
71 Outperform | €1.55B | 17.19 | 35.36% | 1.04% | 7.35% | 5375.64% | |
59 Neutral | €2.44B | 35.12 | 3.96% | 1.22% | 13.32% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €1.40B | 20.17 | 18.13% | 3.51% | 11.04% | 8.29% | |
46 Neutral | €207.44M | 41.66 | 2.03% | 1.91% | -1.19% | -54.66% |
* General Sector Average
ES:FAE
Faes Farma
4.49
1.06
30.87%
ES:ALM
Almirall
11.38
1.28
12.71%
ES:GRF.P
Grifols
6.65
-0.32
-4.55%
ES:RJF
LABORATORIO REIG JOFRE
2.54
-0.08
-2.87%
ES:ROVI
Laboratorios Farmaceuticos Rovi
78.55
27.65
54.33%
ES:PHM
Pharma Mar SA
86.65
-1.38
-1.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.